{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:43Z","timestamp":1791924223991,"version":"4.3.4"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1842919N"],"award-info":[{"award-number":["1842919N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Fondation Contre le Cancer","doi-asserted-by":"publisher","award":["C\/2020\/1380"],"award-info":[{"award-number":["C\/2020\/1380"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Acute kidney injury (AKI), either of pre-renal, renal or post-renal origin, is an important complication in cancer patients, resulting in worse prognosis, withdrawal from effective oncological treatments, longer hospitalizations and increased costs. The aim of this article is to provide a literature review of general and cause-specific treatment strategies for AKI, providing a helpful guide for clinical practice. We propose to classify AKI as patient-related, cancer-related and treatment-related in order to optimize therapeutic interventions. In the setting of patient-related causes, proper assessment of hydration status and avoidance of concomitant nephrotoxic medications is key. Cancer-related causes mainly encompass urinary compression\/obstruction, direct tumoural kidney involvement and cancer-induced hypercalcaemia. Rapid recognition and specific treatment can potentially restore renal function. Finally, a pre-treatment comprehensive evaluation of risks and benefits of each treatment should always be performed to identify patients at high risk of treatment-related renal damage and allow the implementation of preventive measures without losing the potentialities of the oncological treatment. Considering the complexity of this field, a multidisciplinary approach is necessary with the goal of reducing the incidence of AKI in cancer patients and improving patient outcomes. The overriding research goal in this area is to gather higher quality data from international collaborative studies.<\/jats:p>","DOI":"10.1093\/ckj\/sfab292","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:56:41Z","timestamp":1640159801000},"page":"873-884","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of acute kidney injury in cancer patients"],"prefix":"10.1093","volume":"15","author":[{"given":"Pauline","family":"Braet","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Vanessa Re","family":"Sart\u00f2","sequence":"additional","affiliation":[{"name":"Onconephrology Outpatients Clinic, Nephrology and Dialysis, ASST Santi Carlo e Paolo, Fatebenefratelli Sacco, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirovano","sequence":"additional","affiliation":[{"name":"Onconephrology Outpatients Clinic, Nephrology and Dialysis, ASST Santi Carlo e Paolo, Fatebenefratelli Sacco, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-4232","authenticated-orcid":false,"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[{"name":"Onconephrology Outpatients Clinic, Nephrology and Dialysis, ASST Santi Carlo e Paolo, Fatebenefratelli Sacco, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"2022042902150302500_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"2022042902150302500_bib3","first-page":"1","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2022042902150302500_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"key":"2022042902150302500_bib5","first-page":"5181304","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","author":"Kitchlu","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2022042902150302500_bib6","article-title":"Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials","author":"P\u00e9ron","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2022042902150302500_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/ndt\/gfv372","article-title":"Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Reanimation Respiratoire en Onco-Hematologie","volume":"30","author":"Darmon","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2022042902150302500_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2022042902150302500_bib9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"2022042902150302500_bib10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.03770412","article-title":"Onco-nephrology: glomerular diseases with cancer","volume":"7","author":"Cambier","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4111\/icu.2018.59.6.376","article-title":"Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction","volume":"59","author":"Yoon","year":"2018","journal-title":"Investig Clin Urol"},{"key":"2022042902150302500_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MCC.0000000000000253","article-title":"Acute kidney injury in hematological patients","volume":"21","author":"Canet","year":"2015","journal-title":"Curr Opin Crit Care"},{"key":"2022042902150302500_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1258\/ar.2011.110523","article-title":"Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases","volume":"53","author":"Bach","year":"2012","journal-title":"Acta Radiol"},{"key":"2022042902150302500_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0002-9343(77)90427-2","article-title":"Renal failure secondary to leukemic infiltration of the kidneys","volume":"62","author":"Lundberg","year":"1977","journal-title":"Am J Med"},{"key":"2022042902150302500_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0002-9343(62)90289-9","article-title":"Renal lesions associated with malignant lymphomas","volume":"32","author":"Richmond","year":"1962","journal-title":"Am J Med"},{"key":"2022042902150302500_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/1097-0142(19870815)60:4<827::AID-CNCR2820600419>3.0.CO;2-A","article-title":"An autopsy study of 1206 acute and chronic leukemias (1958 to 1982)","volume":"60","author":"Barcos","year":"1987","journal-title":"Cancer"},{"key":"2022042902150302500_bib17","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1681\/ASN.2012040388","article-title":"Mechanisms of light chain injury along the tubular nephron","volume":"23","author":"Sanders","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022042902150302500_bib18","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1172\/JCI125517","article-title":"Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury","volume":"129","author":"Ying","year":"2019","journal-title":"J Clin Invest"},{"key":"2022042902150302500_bib19","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.2019003810","article-title":"How I treat microangiopathic hemolytic anemia in patients with cancer","volume":"137","author":"Thomas","year":"2021","journal-title":"Blood"},{"key":"2022042902150302500_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"key":"2022042902150302500_bib22","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urolonc.2016.02.018","article-title":"Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma","volume":"34","author":"Schmid","year":"2016","journal-title":"Urol Oncol"},{"key":"2022042902150302500_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.7314\/APJCP.2015.16.3.1117","article-title":"Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia","volume":"16","author":"Prasaja","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"2022042902150302500_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.34067\/KID.0000572020","article-title":"Comparison of equations to estimate glomerular filtration rate and their impact on frequency of cisplatin-associated acute kidney injury","volume":"2","author":"Motwani","year":"2021","journal-title":"Kidney360"},{"key":"2022042902150302500_bib26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"2022042902150302500_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022042902150302500_bib28","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors","author":"Garcia-Carro","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2022042902150302500_bib29","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1056\/NEJMe1714680","article-title":"A milestone for CAR T cells","volume":"377","author":"Tran","year":"2017","journal-title":"N Engl J Med"},{"key":"2022042902150302500_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2022042902150302500_bib31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy tisagenlecleucel","volume":"77","author":"Lee","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2022042902150302500_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022042902150302500_bib33","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2022042902150302500_bib34","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.2215\/CJN.02980316","article-title":"Paraprotein-related kidney disease: glomerular diseases associated with paraproteinemias","volume":"11","author":"Motwani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib35","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"2022042902150302500_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2022042902150302500_bib37","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1681\/ASN.2020010054","article-title":"Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy","volume":"31","author":"Klomjit","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022042902150302500_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2016010021","article-title":"Estimating the risk of radiocontrast-associated nephropathy","volume":"28","author":"Wilhelm-Leen","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022042902150302500_bib39","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0140-6736(17)31329-6","article-title":"Management of patients at risk of acute kidney injury","volume":"389","author":"Vanmassenhove","year":"2017","journal-title":"Lancet"},{"key":"2022042902150302500_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N Engl J Med"},{"key":"2022042902150302500_bib41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clon.2010.07.004","article-title":"Percutaneous urinary drainage and ureteric stenting in malignant disease","volume":"22","author":"Allen","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2022042902150302500_bib42","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"2022042902150302500_bib43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"2022042902150302500_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"key":"2022042902150302500_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"key":"2022042902150302500_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"key":"2022042902150302500_bib47","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00432-014-1737-9","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed\/untreated multiple myeloma","volume":"140","author":"P\u00e4nisch","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022042902150302500_bib48","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2215\/CJN.05100418","article-title":"Extracorporeal removal of light chains: new data and continued controversies","volume":"13","author":"Finkel","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022042902150302500_bib50","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022042902150302500_bib51","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"key":"2022042902150302500_bib52","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/S2352-3026(19)30044-4","article-title":"Myeloma cast nephropathy: the dusk of high cutoff haemodialysis","volume":"6","author":"Sall\u00e9e","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022042902150302500_bib53","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3026(19)30090-0","article-title":"High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed","volume":"6","author":"Bridoux","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022042902150302500_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"key":"2022042902150302500_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J Oncol Pract"},{"key":"2022042902150302500_bib56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.kint.2020.06.046","article-title":"KDIGO controversies conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer","volume":"98","author":"Porta","year":"2020","journal-title":"Kidney Int"},{"key":"2022042902150302500_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1006490226104","article-title":"A randomized trial comparing the nephrotoxicity of cisplatin\/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors","volume":"18","author":"Hartmann","year":"2000","journal-title":"Invest New Drugs"},{"key":"2022042902150302500_bib58","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022042902150302500_bib59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"2022042902150302500_bib60","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.clml.2021.01.006","article-title":"Fixed-dose glucarpidase for toxic methotrexate levels and acute kidney injury in adult lymphoma patients: case series","volume":"21","author":"Truong","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022042902150302500_bib61","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042902150302500_bib62","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jcpt.13469","article-title":"Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2022042902150302500_bib63","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022042902150302500_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2022042902150302500_bib65","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2022042902150302500_bib66","doi-asserted-by":"crossref","first-page":"101464","DOI":"10.1016\/j.redox.2020.101464","article-title":"Molecular pathways driving omeprazole nephrotoxicity","volume":"32","author":"Fontecha-Barriuso","year":"2020","journal-title":"Redox Biol"},{"key":"2022042902150302500_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.34067\/KID.0001192019","article-title":"Kidney biopsy should be performed to document the cause of checkpoint inhibitor\u2013associated acute kidney injury: PRO","volume":"1","author":"Eijgelsheim","year":"2020","journal-title":"Kidney360"},{"key":"2022042902150302500_bib68","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"2022042902150302500_bib69","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5858\/arpa.2017-0278-RS","article-title":"Tumor lysis syndrome","volume":"143","author":"Williams","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"2022042902150302500_bib70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/OTT.S103864","article-title":"Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase","volume":"10","author":"Alakel","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2022042902150302500_bib71","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2013results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022042902150302500_bib72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ccr3.495","article-title":"Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm","volume":"4","author":"Sherwood","year":"2016","journal-title":"Clin Case Rep"},{"key":"2022042902150302500_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022042902150302500_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/cei.13497","article-title":"MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab","volume":"203","author":"Elhadad","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2022042902150302500_bib75","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2022042902150302500_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin Exp Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfab292\/42904013\/sfab292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/5\/873\/43462465\/sfab292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/5\/873\/43462465\/sfab292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:19:12Z","timestamp":1651184352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/5\/873\/6482863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":76,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,24]]},"published-print":{"date-parts":[[2022,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfab292","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2021,12,24]]}}}